Deutsche Bank’s Audentes Therapeutics, Inc BOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-33,155
| Closed | -$1.98M | – | 5172 |
|
|
2019
Q4 | $1.98M | Sell |
33,155
-95,438
| -74% | -$3.58M | ﹤0.01% | 1968 |
|
|
2019
Q3 | $3.61M | Buy |
128,593
+16,221
| +14% | +$554K | ﹤0.01% | 1569 |
|
|
2019
Q2 | $4.25M | Buy |
112,372
+92,744
| +473% | +$3.56M | ﹤0.01% | 1919 |
|
|
2019
Q1 | $763K | Sell |
19,628
-125,696
| -86% | -$3.6M | ﹤0.01% | 3168 |
|
|
2018
Q4 | $3.1M | Buy |
145,324
+22,633
| +18% | +$584K | ﹤0.01% | 2119 |
|
|
2018
Q3 | $4.86M | Buy |
122,691
+44,732
| +57% | +$1.67M | ﹤0.01% | 2216 |
|
|
2018
Q2 | $2.98M | Sell |
77,959
-29,640
| -28% | -$1.1M | ﹤0.01% | 2684 |
|
|
2018
Q1 | $3.23M | Buy |
107,599
+56,949
| +112% | +$1.93M | ﹤0.01% | 2546 |
|
|
2017
Q4 | $1.58M | Buy |
50,650
+35,201
| +228% | +$966K | ﹤0.01% | 2891 |
|
|
2017
Q3 | $431K | Sell |
15,449
-4,608
| -23% | -$100K | ﹤0.01% | 3499 |
|
|
2017
Q2 | $382K | Buy |
20,057
+18,478
| +1,170% | +$295K | ﹤0.01% | 3601 |
|
|
2017
Q1 | $25K | Sell |
1,579
-2,428
| -61% | -$39.3K | ﹤0.01% | 4450 |
|
|
2016
Q4 | $71K | Buy |
4,007
+3,045
| +317% | +$52.6K | ﹤0.01% | 4231 |
|
|
2016
Q3 | $17K | Buy |
+962
| New | +$14.6K | ﹤0.01% | 4577 |
|
Deutsche Bank's BOLD Position: Q1 2020 in Review
Deutsche Bank sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2020, closing a stake of 33,155 shares — an estimated $1.98M sold.
Deutsche Bank first reported a position in BOLD in Q3 2016 and held it in 14 quarters. The position peaked at $4.86M in Q3 2018. 0 funds tracked by Wall St. Rank hold BOLD as of Q1 2020.
- Deutsche Bank reported no remaining Audentes Therapeutics, Inc position as of Q1 2020 after selling out during the quarter.
- Deutsche Bank sold 33,155 Audentes Therapeutics, Inc shares in Q1 2020, an estimated $1.98M.
- Deutsche Bank first reported a position in Audentes Therapeutics, Inc in Q3 2016 and held it in 14 quarters.
- Deutsche Bank's Audentes Therapeutics, Inc position peaked at $4.86M in Q3 2018.
- 0 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2020.
Based on Deutsche Bank's 13F filing for Q1 2020, filed 14 May 2020.